Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 899-906

  Giraud, M N ^a   Sanduja, S K ^a   Felder, T B ^b   Illich, P A ^a   Dial, E J ^b   Lichtenberger, L M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; DIPALMITOYLPHOSPHATIDYLCHOLINE; OMEPRAZOLE; SALICYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STOMACH ABSORPTION; STOMACH MUCOSA; STOMACH PH;

EID: 0030747186     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00216.x     Document Type: Article

References (34)

1. Bolting RM. Grygle\vski RJ, Vane JR. The anti-thrombotic actions of aspirin. In: Vane JR, Bolting RM, eds. Aspirin and Other Salicylates. London: Chapman & Hall Medical, 1992: 245-91.
2. Hollander MD. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs, prophylactic and therapeutic strategies. Am J Med 1994: 96: 274-81.
3. Miller DR. Treatment of nonsteroidal anti-inflammatory druginduced gastropathy. Clin Pharm 1992; 11: 690-704.
4. Bjorkman DJ, Kimmey MB. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Dig Dis Sei 1995; 13: 119-29.
5. Miners JO. Drug interactions involving aspirin and salicylic acid. Clin Pharmacokinet 1989; 17: 327-44.
6. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990: 19: 44-66.
7. Oosterhuis B, Jonkman JHG. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion 1989; 44: 9-17.
8. Lichtenberger LM, Ulloa C, Romero JJ, Vanous AL, Illich PA. Dial EJ. Nonsteroidal anti-inflammatory drug-phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 1996; 111: 990-5.
9. Lichtenberger LM, Ulloa C, Vanous A, et al Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther 1996; 277: 1221-7.
10. Wientjes MG, Levy G. Nonlinear pharmacokinetics of aspirin in rats. J Pharmacol Exp Ther 1988; 245: 809-15.
11. Peng GW, Gadalla MAP, Smith V. Peng A, Chiou WL. Simple and rapid high-pressure liquid Chromatographie simultaneous determination of aspirin, salicylic acid and salicyluric acid in plasma. J Pharm Sei 1978; 67: 710-2.
12. Sanduja SK, Metha K, Xu XM, Hsu SM. Sanduja R, Wu KK. Differentiation-associated expression of prostaglandin H and thromboxane synthases in monocytoid leukemia cell lines. Blood 1992; 78: 3178-85.
13. Lichtenberger LM, Wang ZM, Romero JJ, ft al. Nonsteroidal antiinflammatory drug (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAIDinduced gastrointestinal injury. Nat Med 1995: 1: 154-8.
14. Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sei 1972; 6: 379-85.
15. Higgs GA, Salmon JA. Henderson B. Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and anti-inflammatory activity. Proc NatI Acad Sei USA 1987; 84: 1417-20.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-5.
17. Brodie BB, Hogben CAM. Some physico-chemical factors in drug action. J Pharm Pharmacol 1957; 9: 345-80.
18. Crouthamel WG, Tan GH, Dittert LW, Doluisio JT. Drug absorption IV: influence of pH on absorption kinetics of weakly acidic drugs. J Pharm Sei 1971; 60: 1160-3.
19. Powell JR. Donn KH. Histamine H2-antagonist drug interactions in perspective: mechanistic concepts and clinical implications. Am J Med 1984; 77: 57-84.
20. Segre EJ, Sevelius H, Varady J. Effects of antacids on naproxen absorption. New Engl J Med 1974; 291: 582-3.
21. Mason WD, Winer N. Kinetics of aspirin, salicylic acid, salicyluric acid following oral administration of aspirin as a tablet and two buffered solutions. J Pharm Sei 1981; 70: 262-5.
22. Mason WD. Kinetics of aspirin absorption following oral administration of six aqueous solutions with different buffer capacities. J Pharm Sei 1984; 73: 1258-61.
23. Gerber MC, Tejwani GA, Gerber N, Bianchine JR. Drug interactions with cimetidine: an update. Pharmac Ther 1985; 27: 353-70.
24. Howes CA, Pullar T, Sourindhrin T. et al Reduced steady-state plasma concentration of chlorpromazine and indomethacin in patients receiving cimetidine. Eur J Clin Pharmacol 1983; 24: 99-102.
25. Khoury W, Geraci K, Askari A, Johnson M. The effect of cimetidine on aspirin absorption. Gastroenterology 1979; 76: 1169(Abstract).
26. Levy G. Comparison of dissolution and absorption rates of different commercial aspirin tablets. J Pharm Sei 1961; 60: 38892.
27. Shore PA, Brodie BB, Hogben CAM. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957; 119: 361-9.
28. Dotevall G, Ekcenved G. The absorption of acetylsalicylic acid from the stomach in relation to intragastric pH. Scand J Gastroenterol 1976; 11: 801-5.
29. Hollander D, Dadufalza VD, Fairchild A. Intestinal absorption of aspirin. J Lab Clin Med 1981: 98: 591-8.
30. Hogben CA, Tocco MD, Broodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959; 125: 275-82.
31. Fu CJ, Melethil S, Mason WD. The pharmacokinetics of aspirin in rats and the effect of buffer. J Pharmacokinet Biop 1991; 19: 157-73.
32. Giraud MN, Ulloa C, Romero JJ, Lichtenberger LM. Omeprazole reduces the absorption of aspirin in rats. Gastroenterology 1996; 110: 117(Abstract).
33. Levy G. Hydrolysis of aspirin by rat small intestine. J Pharm Sei 1968; 58: 71-5.
34. Habib MJ, Rogers JA. Kinetics of hydrolysis and stabilization of acetylsalicylic acid in liposome formulations. Int J Pharm 1988:44:235-41.